RARE · Ultragenyx Pharmaceutical Inc.

$26.49 +0.11 (+0.42%) At close · Aug 14

Market Cap

$2.61B

98.59M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Emil D. Kakkis	M.D., Ph.D. President and Chief Executive Officer	$861,100	—	$8,364,938	$1,847,356	$299,663	$32,478	$11,405,535
Erik Harris	Chief Commercial Officer and Executive Vice President	$619,692	—	$2,407,560	$712,257	$291,563	$14,000	$4,045,072
Eric Crombez	Chief Medical Officer and Executive Vice President	$630,231	—	$2,407,560	$712,257	$238,125	$14,000	$4,002,173
Howard Horn	Chief Financial Officer, Corporate Strategy and Executive Vice President	$604,385	—	$2,241,463	$663,134	$227,625	$14,000	$3,750,607
Karah Parschauer	Chief Legal Officer and Corporate Affairs, Executive Vice President	$585,342	—	$2,075,430	$614,011	$220,530	$14,000	$3,509,313

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Emil D. Kakkis	M.D., Ph.D. President and Chief Executive Officer	$856,008	—	$9,374,511	$2,715,600	$757,768	$13,800	$13,717,687
Eric Crombez	Chief Medical Officer and Executive Vice President	$591,846	—	$2,271,944	$1,038,603	$382,030	$13,800	$4,298,223
Howard Horn	Chief Financial Officer, Corporate Strategy and Executive Vice President	$590,000	—	$2,271,944	$1,076,335	$343,970	$13,800	$4,296,049
Erik Harris	Chief Commercial Officer and Executive Vice President	$604,231	—	$2,271,944	$1,038,603	$367,235	$13,800	$4,295,813
John R. Pinion II	Chief Quality Officer and Executive Vice President, Translational Sciences	$570,366	—	$2,084,548	$1,121,271	$339,768	$13,800	$4,129,753

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Emil D. Kakkis	M.D., Ph.D. President and Chief Executive Officer	$823,692	—	$9,456,663	$2,161,782	$622,656	$13,200	$13,077,993
Howard Horn	Chief Financial Officer, Corporate Strategy and Executive Vice President	$124,808	$60,000	$2,867,459	$2,888,773	—	—	$5,941,040
Erik Harris	Chief Commercial Officer and Executive Vice President	$585,969	—	$2,169,750	$1,020,050	$279,598	$13,200	$4,068,567
John R. Pinion II	Chief Quality Officer and Executive Vice President, Translational Sciences	$552,092	—	$2,169,750	$1,020,050	$294,761	$13,200	$4,049,853
Karah Parschauer	Chief Legal Officer & Corporate Affairs and Executive Vice President	$535,169	—	$2,169,750	$1,020,050	$298,375	$13,200	$4,036,544

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Emil D. Kakkis	M.D., Ph.D. President and Chief Executive Officer	$796,154	—	$7,463,295	$3,310,681	$558,000	$12,200	$12,140,330
Mardi Dier	Former Chief Financial Officer and Executive Vice President	$607,346	—	$2,928,368	$892,550	—	$8,492	$4,436,756
Camille Bedrosian	Chief Medical Officer and Executive Vice President	$596,000	—	$2,007,768	$892,550	$246,750	$12,200	$3,755,268
Erik Harris	Chief Commercial Officer and Executive Vice President	$566,331	—	$2,007,768	$892,550	$269,706	$12,200	$3,748,555
John R. Pinion II	Chief Quality Officer and Executive Vice President, Translational Sciences	$533,315	—	$2,007,768	$892,550	$260,678	$12,200	$3,706,511

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Emil D. Kakkis	M.D., Ph.D. President and Chief Executive Officer	$768,846	—	$5,410,512	$2,835,580	$499,100	$8,700	$9,522,738
Camille Bedrosian	Chief Medical Officer and Executive Vice President	$567,123	—	$1,653,212	$866,427	$249,260	$8,700	$3,344,722
Mardi Dier	Former Chief Financial Officer and Executive Vice President	$561,539	—	$1,653,212	$866,427	$247,523	$3,173	$3,331,874
Erik Harris	Chief Commercial Officer and Executive Vice President	$543,846	—	$1,653,212	$866,427	$245,025	$8,700	$3,317,210
John R. Pinion II	Chief Quality Officer and Executive Vice President, Translational Sciences	$509,939	—	$1,653,212	$866,427	$224,942	$8,700	$3,263,220

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Mardi Dier	Former Chief Financial Officer and Executive Vice President	$116,346	$100,000	$3,820,000	$2,084,296	—	—	$6,120,642
Emil D. Kakkis	M.D., Ph.D. President and Chief Executive Officer	$759,231	—	$1,906,720	$1,802,869	$668,850	$6,550	$5,144,220
Erik Harris	Chief Commercial Officer and Executive Vice President	$501,247	—	$723,432	$707,007	$292,613	—	$2,224,299
Camille Bedrosian	Chief Medical Officer and Executive Vice President	$546,686	—	$695,392	$674,871	$297,731	—	$2,214,680
John R. Pinion II	Chief Quality Officer and Executive Vice President, Translational Sciences	$480,063	—	$723,432	$707,007	$267,138	—	$2,177,640

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Emil D. Kakkis	M.D., Ph.D. President and Chief Executive Officer	$714,000	—	$2,702,000	$2,650,784	$479,808	$6,550	$6,553,142
John R. Pinion II	Chief Quality Officer and Executive Vice President, Translational Sciences	$447,690	—	$1,756,300	$923,578	$205,490	—	$3,333,238
Shalini Sharp	Chief Financial Officer and Executive Vice President	$484,548	—	$945,700	$923,758	$218,178	$33,337	$2,605,521
Camille Bedrosian	Chief Medical Officer and Executive Vice President	$511,186	—	$878,150	$863,513	$230,076	$2,729	$2,485,654
Thomas Kassberg	Chief Business Officer and Executive Vice President	$474,000	—	$878,150	$863,513	$206,901	$33,937	$2,456,501
Erik Harris	Chief Commercial Officer and Executive Vice President	$418,077	—	$691,705	$962,122	$201,488	—	$2,273,392

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Camille Bedrosian	Chief Medical Officer and Executive Vice President	$442,308	$210,000	$990,000	$2,906,983	$189,274	$107,727	$4,846,292
Emil D. Kakkis	M.D., Ph.D. President and Chief Executive Officer	$679,952	—	$944,385	$2,753,513	$428,400	$39,377	$4,845,627
Shalini Sharp	Chief Financial Officer and Executive Vice President	$470,435	—	$339,010	$1,019,820	$198,695	$32,827	$2,060,787
Thomas Kassberg	Chief Business Officer and Executive Vice President	$441,340	—	$242,150	$786,718	$189,600	$32,852	$1,692,660
John R. Pinion II	Chief Quality Officer and Executive Vice President, Translational Sciences	$430,320	—	$217,935	$728,443	$188,030	$36,346	$1,601,074

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Emil D. Kakkis	M.D., Ph.D. President and Chief Executive Officer	$638,115	—	$1,319,303	$4,295,234	$393,000	$39,247	$6,684,899
Shalini Sharp	Chief Financial Officer and Executive Vice President	$455,785	—	$424,043	$1,541,879	$188,315	$32,697	$2,642,719
Thomas Kassberg	Chief Business Officer and Executive Vice President	$418,443	—	$335,243	$1,376,678	$168,600	$32,697	$2,331,661
John R. Pinion II	Chief Quality Officer and Executive Vice President, Translational Sciences	$412,568	—	$308,603	$991,208	$170,459	$36,491	$1,919,329

Executive changes

Person	Role	Change	Effective	Filed
Daniel G. Welch	Class I Director	Appointed	2026-05-14	2026-05-18
Shehnaaz Suliman	Class I Director	Appointed	2026-05-14	2026-05-18
Emil D. Kakkis	Class I Director	Appointed	2026-05-14	2026-05-18
Amrit Ray, M.D.	Class III Director	Appointed	2025-05-15	2025-05-19
Matthew K. Fust	Class III Director	Appointed	2025-05-15	2025-05-19
Corsee Sanders, Ph.D.	Class II Director	Appointed	2024-06-18	2024-06-21
Michael Narachi	Class II Director	Appointed	2024-06-18	2024-06-21
Deborah Dunsire, M.D.	Class II Director	Appointed	2024-06-18	2024-06-21
Howard Horn	Chief Financial Officer and Executive Vice President, Corporate Strategy	Appointed	2023-10-09	2023-09-08
Howard Horn	Chief Financial Officer and Executive Vice President, Corporate Strategy	Appointed	2023-10-16	2023-07-12
Daniel G. Welch	Class I Director	Appointed	2023-06-07	2023-06-13
Shehnaaz Suliman, M.D.	Class I Director	Appointed	2023-06-07	2023-06-13
Emil D. Kakkis, M.D., Ph.D.	Class I Director	Appointed	2023-06-07	2023-06-13
Lars Ekman, M.D., Ph.D.	Board of Directors	Retired	2023-06-07	2023-03-23
Eric Crombez, M.D.	Executive Vice President, Chief Medical Officer	Appointed	2023-05-01	2023-03-14
Camille L. Bedrosian, M.D.	Strategic Development Advisor	Appointed	2023-05-01	2023-03-14
Mardi Dier	Executive Vice President and Chief Financial Officer	Resigned	2022-11-15	2022-11-10
Amrit Ray, M.D.	Class III director	Appointed	2022-04-19	2022-04-22

Key facts CIK 1515673 CUSIP 90400D108 13F (30d) 327 filings 293 filers Visit website Investor relations